Harbour Investments’s Viridian Therapeutics VRDN Stock Holding History

Harbour Investments’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-66	Closed	-$1.16K	–	3376
2024 Q1	$1.16K	Buy	+66	New	+$1.28K	﹤0.01%	2898

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Harbour Investments's VRDN Position: Q2 2024 in Review

Harbour Investments sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 66 shares — an estimated $1.16K sold.

Harbour Investments first reported a position in VRDN in Q1 2024 and held it in 1 quarter. The position peaked at $1.16K in Q1 2024. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

Harbour Investments reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
Harbour Investments sold 66 Viridian Therapeutics shares in Q2 2024, an estimated $1.16K.
Harbour Investments first reported a position in Viridian Therapeutics in Q1 2024 and held it in 1 quarter.
Harbour Investments's Viridian Therapeutics position peaked at $1.16K in Q1 2024.
138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Harbour Investments's 13F filing for Q2 2024, filed 26 Jul 2024.